Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States
Ryan A Denu, Sreevalsa Appukkuttan, Brian Hocum, Nick Liao, Arvind Katta, Jihaeng Heo, Bridgette Schroader, Risho Singh · 2026
Read Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States by Ryan A Denu, Sreevalsa Appukkuttan, Brian Hocum, Nick Liao, Arvind Katta, Jihaeng Heo, Bridgette Schroader, Risho Singh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353357.txt.
Description
Ryan A Denu led a team of eight authors on this 2026 claims study of a cancer drug used in the United States. Regorafenib is approved as a later option for advanced gastrointestinal stromal tumors, a rare gut cancer, after earlier targeted drugs fail. The team mined insurance records spanning 2015 to 2023 for patients who filled the drug.
Patients starting on a lower dose stayed on treatment about as long as those on the standard dose, and waited similar times before switching therapy. People who had taken only one earlier drug fared longer than those who had taken two. Denu calls for outcome studies next.
Catalog record
| CREATOR | Ryan A Denu, Sreevalsa Appukkuttan, Brian Hocum, Nick Liao, Arvind Katta, Jihaeng Heo, Bridgette Schroader, Risho Singh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25713 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |